MCID: INF037
MIFTS: 53

Inflammatory Bowel Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Inflammatory Bowel Disease

MalaCards integrated aliases for Inflammatory Bowel Disease:

Name: Inflammatory Bowel Disease 12 36 29 6 3 15 17
Inflammatory Bowel Diseases 54 44 15 71
Bowel Disease, Inflammatory 39

Classifications:



External Ids:

Disease Ontology 12 DOID:0050589
KEGG 36 H01227
MeSH 44 D015212
NCIt 50 C3138
SNOMED-CT 67 155759008
UMLS 71 C0021390

Summaries for Inflammatory Bowel Disease

KEGG : 36 Inflammatory bowel disease (IBD) is a heterogeneous group of chronic disorders, which includes Crohn's disease and ulcerative colitis. Patients suffer chronically from abdominal pain, diarrhea, bleeding, and malabsorption. In most patients, these disorders are manifested in adolescence or adulthood, however, they may present in infancy and may be inherited as an autosomal recessive trait. It has been reported that mutations in genes encoding the IL10R subunit proteins were found in patients with early-onset enterocolitis, involving hyperinflammatory immune responses in the intestine. Additional genes associated with the disease have been identified.

MalaCards based summary : Inflammatory Bowel Disease, also known as inflammatory bowel diseases, is related to inflammatory bowel disease 15 and inflammatory bowel disease 8. An important gene associated with Inflammatory Bowel Disease is NRON (Non-Coding Repressor Of NFAT), and among its related pathways/superpathways are Inflammatory bowel disease and Antigen processing and presentation. The drugs Copper and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and neutrophil.

Disease Ontology : 12 An intestinal disease characterized by inflammation located in all parts of digestive tract.

CDC : 3 Inflammatory Bowel Disease (IBD) is a broad term that describes conditions characterized by chronic inflammation of the gastrointestinal tract. The two most common inflammatory bowel diseases are ulcerative colitis and Crohn's disease. Inflammation affects the entire digestive tract in Crohn's disease and only the large intestine (also called the colon) in ulcerative colitis. Both illnesses involved an abnormal response to the body's immune system.

Wikipedia : 74 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.... more...

Related Diseases for Inflammatory Bowel Disease

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 3
Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 5
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 6
Inflammatory Bowel Disease 4 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 12
Inflammatory Bowel Disease 13 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 15 Inflammatory Bowel Disease 16
Inflammatory Bowel Disease 17 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 19 Inflammatory Bowel Disease 20
Inflammatory Bowel Disease 21 Inflammatory Bowel Disease 22
Inflammatory Bowel Disease 23 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Autosomal Recessive Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 28, Autosomal Recessive
Inflammatory Bowel Disease 29 Inflammatory Bowel Disease 30
Inflammatory Bowel Disease 28 Inflammatory Bowel Disease 25
Rare Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1221)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 15 33.4 NOD2 IBD15
2 inflammatory bowel disease 8 33.4 NOD2 IBD8
3 inflammatory bowel disease 7 33.4 NOD2 IBD7
4 inflammatory bowel disease 9 33.3 NOD2 IBD9
5 inflammatory bowel disease 2 33.3 NOD2 IBD2
6 inflammatory bowel disease 6 33.3 NOD2 IBD6
7 inflammatory bowel disease 3 33.2 NOD2 IBD3
8 inflammatory bowel disease 18 33.2 NOD2 IBD18
9 inflammatory bowel disease 5 33.0 NOD2 IBD5
10 inflammatory bowel disease 25, autosomal recessive 11.9
11 ulcerative colitis 11.9
12 crohn's disease 11.8
13 inflammatory bowel disease 1 11.8
14 inflammatory bowel disease 10 11.8
15 inflammatory bowel disease 17 11.8
16 inflammatory bowel disease 19 11.8
17 inflammatory bowel disease 28, autosomal recessive 11.8
18 inflammatory bowel disease 13 11.8
19 inflammatory bowel disease 14 11.8
20 inflammatory bowel disease 29 11.7
21 inflammatory bowel disease, immunodeficiency, and encephalopathy 11.7
22 inflammatory bowel disease 30 11.7
23 inflammatory bowel disease 4 11.7
24 inflammatory bowel disease 20 11.7
25 inflammatory bowel disease 24 11.7
26 inflammatory bowel disease 28 11.7
27 inflammatory bowel disease 12 11.7
28 inflammatory bowel disease 16 11.7
29 inflammatory bowel disease 21 11.7
30 inflammatory bowel disease 26 11.7
31 inflammatory bowel disease 22 11.7
32 inflammatory bowel disease 23 11.7
33 inflammatory bowel disease 27 11.7
34 inflammatory bowel disease 11 11.7
35 inflammatory bowel disease 25 11.6
36 cholangitis, primary sclerosing 11.6
37 gastrointestinal defects and immunodeficiency syndrome 11.5
38 immunodeficiency 57 with autoinflammation 11.5
39 crohn's colitis 11.5
40 colitis 11.4
41 spondyloarthropathy 1 11.4
42 irritable bowel syndrome 11.4
43 immunodeficiency, common variable, 8, with autoimmunity 11.3
44 ileocolitis 11.3
45 proctitis 11.3
46 collagenous colitis 11.3
47 ileitis 11.3
48 glycogen storage disease ib 11.2
49 immunodeficiency, common variable, 11 11.2
50 lymphoproliferative syndrome, x-linked, 1 11.2

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease:



Diseases related to Inflammatory Bowel Disease

Symptoms & Phenotypes for Inflammatory Bowel Disease

Drugs & Therapeutics for Inflammatory Bowel Disease

Drugs for Inflammatory Bowel Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Copper Approved, Investigational Phase 4 7440-50-8 27099
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Prucalopride Approved Phase 4 179474-81-8
4
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
7
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Fidaxomicin Approved Phase 4 873857-62-6
11
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
15
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
16
Zinc oxide Approved Phase 4 1314-13-2
17
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
18
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
19
Tofacitinib Approved, Investigational Phase 4 477600-75-2
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
22
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Ustekinumab Approved, Investigational Phase 4 815610-63-0
26
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
27
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
28 Copper Supplement Phase 4
29 Serotonin Receptor Agonists Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Analgesics Phase 4
33 Iron Supplement Phase 4
34 Diphosphonates Phase 4
35 calcium channel blockers Phase 4
36 Mesalamine Phase 4 89-57-6
37 Psychotropic Drugs Phase 4
38 Narcotics Phase 4
39 Anti-Anxiety Agents Phase 4
40 Hypnotics and Sedatives Phase 4
41 Anesthetics, Intravenous Phase 4
42 GABA Modulators Phase 4
43 Anesthetics, General Phase 4
44 Ferric Oxide, Saccharated Phase 4
45 Anti-Ulcer Agents Phase 4
46 Antacids Phase 4
47 Cyclooxygenase 2 Inhibitors Phase 4
48 Cyclooxygenase Inhibitors Phase 4
49 Proton Pump Inhibitors Phase 4
50 Dopamine Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 854)
# Name Status NCT ID Phase Drugs
1 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
2 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
3 Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate Unknown status NCT03860012 Phase 4 Folic Acid
4 Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD) Unknown status NCT02958501 Phase 4 Colecalciferol
5 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
6 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
7 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
8 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
9 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 A Randomized, Data Collection Program To Determine the Efficacy and Safety of Risedronate (Actonel) Therapy Plus Calcium and Vitamin D Supplementation Versus Placebo Plus Calcium and Vitamin D Supplementation in the Treatment of Low Bone Mineral Density in Crohn's Disease Patients Completed NCT01215890 Phase 4 risedronate;placebo
11 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
12 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
13 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
14 Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography Completed NCT02946203 Phase 4
15 Gene Regulation by Thiazolidinediones Completed NCT00567593 Phase 4 Rosiglitazone
16 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy Completed NCT00746395 Phase 4 Lubiprostone;Placebo
17 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
18 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
19 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
20 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
21 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
22 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
23 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
24 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
25 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
26 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Completed NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
27 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
28 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
29 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
30 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
31 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
32 Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Recruiting NCT03885713 Phase 4
33 Chronotherapy in Inflammatory Bowel Disease Recruiting NCT04304950 Phase 4 Evening Group;Morning Group
34 The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib Recruiting NCT03591770 Phase 4
35 De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring Recruiting NCT04646187 Phase 4
36 Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD). Recruiting NCT04626947 Phase 4
37 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Recruiting NCT03798691 Phase 4
38 Evaluation of the Safety and Effectiveness of Switching From Originator (Humira®) to Biosimilar (Imraldi®) Adalimumab in Flanders (SafE-OrBi) Recruiting NCT04045782 Phase 4 single arm
39 A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease Recruiting NCT03466983 Phase 4 Iron Isomaltoside;Ferric Carboxymaltose
40 Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases Recruiting NCT01793831 Phase 4
41 Control Crohn Safe With Episodic Adalimumab Monotherapy as First Line Treatment Study. Recruiting NCT03917303 Phase 4 Adalimumab;standard step-up care
42 Does Bowel Preparation (Either as a Single or Divided Dose) Produce Better Cleansing and Diagnostic Yield Than no Preparation at All in Small Bowel Capsule Endoscopy Recruiting NCT03351972 Phase 4 Klean Prep
43 A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION Active, not recruiting NCT03281304 Phase 4 CP-690,500 5 mg;CP-690,550 10 mg
44 Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients Active, not recruiting NCT03172377 Phase 4
45 Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation Active, not recruiting NCT02994836 Phase 4 Anti-TNF discontinuation: Physiological saline solution;Anti-TNF discontinuation: Physiological saline solution
46 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Active, not recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
47 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Active, not recruiting NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
48 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions Not yet recruiting NCT03629379 Phase 4 Ustekinumab;Vedolizumab
49 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis Terminated NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
50 Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease Terminated NCT00205062 Phase 4

Search NIH Clinical Center for Inflammatory Bowel Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


clidinium
Clidinium bromide
Cromolyn
Cromolyn Sodium

Cochrane evidence based reviews: inflammatory bowel diseases

Genetic Tests for Inflammatory Bowel Disease

Genetic tests related to Inflammatory Bowel Disease:

# Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 29

Anatomical Context for Inflammatory Bowel Disease

MalaCards organs/tissues related to Inflammatory Bowel Disease:

40
Colon, T Cells, Neutrophil, Skin, Small Intestine, Endothelial, Bone

Publications for Inflammatory Bowel Disease

Articles related to Inflammatory Bowel Disease:

(show top 50) (show all 37180)
# Title Authors PMID Year
1
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. 61 54
20361960 2010
2
Association analysis of myosin IXB and type 1 diabetes. 61 54
20303373 2010
3
Anti-TNF therapy in inflammatory bowel diseases: a huge review. 54 61
20485259 2010
4
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. 61 54
20485703 2010
5
IL-6 may modulate the skeletal response to glucocorticoids during exacerbations of inflammatory bowel disease. 61 54
20229252 2010
6
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 61 54
20454450 2010
7
Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease. 54 61
20184972 2010
8
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 61 54
20228197 2010
9
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. 54 61
19710105 2010
10
Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. 61 54
19878610 2010
11
Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole-blood model. 54 61
20138213 2010
12
GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. 61 54
20331905 2010
13
Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. 61 54
20061984 2010
14
Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. 61 54
20210765 2010
15
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs. 54 61
19960028 2010
16
Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. 61 54
19714744 2010
17
Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia. 54 61
20446955 2010
18
[Use of TNFalpha antibodies in treatment of inflammatory bowel disease]. 61 54
20160771 2010
19
Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. 54 61
20175817 2010
20
Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia. 54 61
20101775 2010
21
Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. 54 61
19698701 2010
22
Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions. 61 54
19808045 2010
23
Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients. 61 54
20066736 2010
24
Dislocation of Rab13 and vasodilator-stimulated phosphoprotein in inactive colon epithelium in patients with Crohn's disease. 61 54
19885626 2009
25
Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. 54 61
19740775 2009
26
Sulphasalazine accelerates apoptosis in neutrophils exposed to immune complex: Role of caspase pathway. 61 54
19473188 2009
27
Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. 61 54
19363798 2009
28
Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. 61 54
19839006 2009
29
Role of ATG16L1 Thr300Ala polymorphism in inflammatory bowel disease: a Study in the Spanish population and a meta-analysis. 54 61
19575361 2009
30
Interleukin-10 in inflammatory bowel disease. 54 61
19890110 2009
31
Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. 61 54
19639558 2009
32
Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? 61 54
19711064 2009
33
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. 54 61
19817673 2009
34
PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. 61 54
19462432 2009
35
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. 54 61
19874614 2009
36
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. 54 61
19648026 2009
37
A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. 61 54
19740306 2009
38
[TNF-alpha blocking therapy in chronic inflammatory bowel disease]. 54 61
19740722 2009
39
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. 54 61
19291780 2009
40
Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. 54 61
19322899 2009
41
[The cytokines in inflammatory bowel disease]. 54 61
19724079 2009
42
pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. 61 54
19570976 2009
43
Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. 61 54
19327358 2009
44
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. 54 61
19682195 2009
45
Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. 61 54
19617917 2009
46
Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. 61 54
19578817 2009
47
Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs. 61 54
19604082 2009
48
Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patients. 54 61
19516190 2009
49
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. 54 61
19268443 2009
50
Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). 54 61
19184329 2009

Variations for Inflammatory Bowel Disease

ClinVar genetic disease variations for Inflammatory Bowel Disease:

6 (show all 21)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL10RB NM_000628.5(IL10RB):c.*365C>T SNV Uncertain significance 339702 rs886057005 21:34669027-34669027 21:33296722-33296722
2 IL10RB NM_000628.5(IL10RB):c.*593_*594TC[1] Microsatellite Uncertain significance 339705 rs886057007 21:34669255-34669256 21:33296950-33296951
3 IL10RB NM_000628.5(IL10RB):c.*616del Deletion Uncertain significance 339706 rs5843596 21:34669259-34669259 21:33296954-33296954
4 IL10 NM_000572.3(IL10):c.94C>A (p.His32Asn) SNV Uncertain significance 526787 rs376787667 1:206945687-206945687 1:206772342-206772342
5 IL10 NM_000572.3(IL10):c.58C>T (p.Pro20Ser) SNV Uncertain significance 526788 rs141219090 1:206945723-206945723 1:206772378-206772378
6 IL10 NM_000572.3(IL10):c.514A>G (p.Met172Val) SNV Uncertain significance 662170 rs768418064 1:206942004-206942004 1:206768659-206768659
7 IL10 NM_000572.3(IL10):c.134G>A (p.Arg45Gln) SNV Uncertain significance 840379 1:206945647-206945647 1:206772302-206772302
8 IL10 NM_000572.3(IL10):c.507A>C (p.Glu169Asp) SNV Uncertain significance 939398 1:206942011-206942011 1:206768666-206768666
9 IL10 NM_000572.3(IL10):c.71C>G (p.Thr24Ser) SNV Uncertain significance 946285 1:206945710-206945710 1:206772365-206772365
10 IL10 NM_000572.3(IL10):c.383G>T (p.Arg128Leu) SNV Uncertain significance 949531 1:206943235-206943235 1:206769890-206769890
11 IL10 NM_000572.3(IL10):c.274G>A (p.Glu92Lys) SNV Uncertain significance 956183 1:206944356-206944356 1:206771011-206771011
12 IL10 NM_000572.3(IL10):c.530G>A (p.Arg177Gln) SNV Uncertain significance 970779 1:206941988-206941988 1:206768643-206768643
13 IL10RA NM_001558.4(IL10RA):c.*356dup Duplication Likely benign 302563 rs146951811 11:117870710-117870711 11:117999995-117999996
14 IL10 NM_000572.3(IL10):c.345C>T (p.Asn115=) SNV Likely benign 745482 rs5743626 1:206944285-206944285 1:206770940-206770940
15 IL10 NM_000572.3(IL10):c.228T>C (p.Gly76=) SNV Likely benign 756187 rs139352858 1:206944402-206944402 1:206771057-206771057
16 IL10 NM_000572.3(IL10):c.336G>C (p.Leu112=) SNV Likely benign 757750 rs767727378 1:206944294-206944294 1:206770949-206770949
17 IL10 NM_000572.3(IL10):c.56G>A (p.Ser19Asn) SNV Likely benign 729261 rs139073251 1:206945725-206945725 1:206772380-206772380
18 KRT8 NM_002273.4(KRT8):c.187A>G (p.Ile63Val) SNV Likely benign 66533 rs59536457 12:53298579-53298579 12:52904795-52904795
19 IL10 NM_000572.3(IL10):c.165+8T>C SNV Benign 729486 rs530302888 1:206945608-206945608 1:206772263-206772263
20 IL10RB NM_000628.5(IL10RB):c.*615_*616del Deletion Benign 339707 rs5843596 21:34669259-34669260 21:33296954-33296955
21 IL10 NM_000572.3(IL10):c.43G>A (p.Gly15Arg) SNV Benign 456662 rs145922845 1:206945738-206945738 1:206772393-206772393

Expression for Inflammatory Bowel Disease

Search GEO for disease gene expression data for Inflammatory Bowel Disease.

Pathways for Inflammatory Bowel Disease

Pathways related to Inflammatory Bowel Disease according to KEGG:

36
# Name Kegg Source Accession
1 Inflammatory bowel disease hsa05321
2 Antigen processing and presentation hsa04612
3 Cytokine-cytokine receptor interaction hsa04060
4 JAK-STAT signaling pathway hsa04630
5 Autophagy - animal hsa04140

GO Terms for Inflammatory Bowel Disease

Sources for Inflammatory Bowel Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....